GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the three and nine months ended September 30, 2017 after the market close on Thursday, November 9, and host a conference call at 8:30am Eastern Time on Friday, November 10, 2017.
|Conference Call Details|
|Date:||Friday, November 10|
|Time:||8:30am Eastern Time|
|Replays will be available through November 24:|
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
President and CEO